Asia Cup final: India beat Malaysia 2-1 to win third Asia Cup title

New Delhi, Aug 6: The BCCI on Thursday suspended the IPL title sponsorship deal with Chinese mobile phone company Vivo for the event's upcoming edition amid heightened tensions in Sino-India diplomatic ties.

The BCCI sent out a one-line statement, without giving details, saying that Vivo would not be associated with the IPL this year. "The Board of Control for Cricket in India (BCCI) and vivo Mobile India Pvt Ltd have decided to suspend their partnership for Indian Premier League in 2020," the statement said.

Meanwhile, Vivo released its own statement saying that the two entities "have mutually decided to pause their partnership for the 2020 season".

Vivo won the IPL title sponsorship rights for five years from 2018 to 2022 for a reported sum of Rs 2,190 crore, approximately Rs 440 crore per annum.

The two parties are now working out a plan in which Vivo might come back for a fresh three-year period starting 2021 on revised terms.

However, a top BCCI official offered a different view. "Here we are talking about diplomatic tensions and you expect that after November, when IPL ends and before the next IPL starts in April 2021, there would be no anti-China sentiment? Are we serious?" a veteran BCCI official said on conditions of anonymity.

The anti-China sentiment in the country peaked after the violent face-off between the Indian and Chinese troops in eastern Ladakh. India lost 20 soldiers in the clash, while China also acknowledged unspecified casualties.

The stand-off at the Line of Actual Control (LAC) caused outrage across India with several calls for boycotts of Chinese companies and products.

The BCCI is now likely to float a tender for new IPL title sponsors as mandated by its constitution. The glitzy T20 league starts on Sept. 19 in the UAE, forced out of India due to the rising COVID-19 cases.

The new development is in stark contrast to what came out of Sunday's IPL's Governing Council meeting, where it was decided that Vivo, along with all the other sponsors, will remain on board.

This was after the BCCI had announced in June that all sponsorship deals pertaining to IPL will be reviewed in the aftermath of the clash in the Galwan Valley.

However, after Sunday's meeting, there was a huge backlash on social media about the BCCI holding on to Vivo.

Both parties then began thrashing out an amicable separation plan, at least for this season.

However, the end of this deal could spell losses for the franchises as they get a substantial share from the sponsorship pool. Half of the annual Vivo sponsorship money is distributed equally among eight franchises, which comes to Rs 27.5 crore.

"As of now, it will be very difficult for the BCCI to match the sponsorship amount at such short notice. Therefore, both BCCI and the franchises should be prepared to lose out on some money -- BCCI more but each franchise from Vivo's exit will potentially lose 15 crore," the official said.

"This year will be difficult for everyone but the show must go on," the official said.

If everything goes as Russia’s expectation, it will be world’s first country to approve a coronavirus vaccine for widespread in the second week of August despite safety and efficacy concerns, according to a report. The adenoviral vector-based vaccine developed by Russian military and government researchers is currently in phase 2 trials.

According to a report from CNN, Russian officials are hoping to get approval for the COVID-19 vaccine developed by the Moscow-based Gamaleya Institute on Agust 10 or even before that. The officials told the outlet that the vaccine will be approved for public use with frontline healthcare workers receiving it first.

“It’s a Sputnik moment,” said Kirill Dmitriev, head of Russia’s sovereign wealth fund, which is financing Russian vaccine research, referring to the successful 1957 launch of the world’s first satellite by the Soviet Union, according to CNN.

“Americans were surprised when they heard Sputnik’s beeping. It’s the same with this vaccine. Russia will have got there first,” he was quoted as saying.

However, Russia is yet to release the scientific data on its coronavirus vaccine trials, hence, questions remain about the safety and efficacy of the vaccine, said the report. The vaccine is in the second phase of testing with developers planning to launch the phase 3 trials sometime after August 3.

Earlier, Interfax reported, citing Health Minister Mikhail Murashko, that the vaccine will be widely used in parallel with phase 3 trials. He said the country plans to vaccinate medics who are at high-risk for COVID-19 next month before clinical trials are completed.

Murashko added that individuals at higher risk of getting infected with the coronavirus such as older people or those with health conditions will also be prioritised for the vaccine, although he did not estimate or reveal when that would happen. The minister added 800 people will be recruited for the phase 3 trials.

Meanwhile, health officials were more cautious considering the fact that human testing of the vaccine is incomplete, and the state registration is expected to begin after August 3, reported The Moscow Times.

On Monday, Moderna and Pfizer announced the commencement of the final phase 3 trials of their candidate vaccines against the SARS-CoV-2 virus, which has so far claimed at least 654,477 lives and infected 16,514,500 people worldwide. 

Researchers will recruit up to 30,000 volunteers in separate trials both backed by the US government. India's first indigenous coronavirus vaccine, COVAXIN, is undergoing phase 1 human clinical trials across the country. More than 150 COVID-19 vaccines are being developed all over the world with at least six candidates already in late-stage clinical trials.